Evidence map›Paper›PMID 30527624›Full record

ArticleEBioMedicine2019

A new gold(I) complex-Au(PPh

Xiaofen Li, Qingtian Huang, Huidan Long, Peiquan Zhang, Huabo Su, Jinbao Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Xiaofen LiAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, China; Protein Modification and Degradation Lab, State Key Lab of Respiratory Disease, Guangzhou Medical University, Guangdong, China.
Qingtian HuangProtein Modification and Degradation Lab, State Key Lab of Respiratory Disease, Guangzhou Medical University, Guangdong, China.
Huidan LongProtein Modification and Degradation Lab, State Key Lab of Respiratory Disease, Guangzhou Medical University, Guangdong, China.
Peiquan ZhangProtein Modification and Degradation Lab, State Key Lab of Respiratory Disease, Guangzhou Medical University, Guangdong, China.
Huabo SuAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, China; Protein Modification and Degradation Lab, State Key Lab of Respiratory Disease, Guangzhou Medical University, Guangdong, China; Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA, USA.
Jinbao LiuAffiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, Guangdong 510095, China; Protein Modification and Degradation Lab, State Key Lab of Respiratory Disease, Guangzhou Medical University, Guangdong, China. Electronic address: jliu@gzhmu.edu.cn.
Guangzhou Medical University · CNAugusta University · US

Funding

Neddylation and cardiac protein quality controlR01HL124248 · NHLBI · AUGUSTA UNIVERSITY · PI SU, HUABO · 2014 to 2024
$4.1M
NHLBI NIH HHS R01 HL124248
6 · The paper itself

Abstract

backgroundUbiquitin-proteasome system (UPS) is integral to cell survival by maintaining protein homeostasis, and its dysfunction has been linked to cancer and several other human diseases. Through counteracting ubiquitination, deubiquitinases (DUBs) can either positively or negatively regulate UPS function, thereby representing attractive targets of cancer therapies. Previous studies have shown that metal complexes can inhibit tumor growth through targeting the UPS; however, novel metal complexes with higher specificity for cancer therapy are still lacking.

methodsWe synthesized a new gold(I) complex, Au(PPh

findingsHere we report that (i) a new gold(I) complex-pyrithione, i.e., Au(PPh

interpretationTogether, this study discovers a new gold(I) complex to be an effective inhibitor of the DUBs and a potential anti-cancer drug. FUND: The National High Technology Research and Development Program of China, the project of Guangdong Province Natural Science Foundation, the projects from Foundation for Higher Education of Guangdong, the project from Guangzhou Medical University for Doctor Scientists, the Medical Scientific Research Foundation of Guangdong Province, and the Guangzhou Key Medical Discipline Construction Project Fund.

Indexed as

A549 CellsAnimalsCell Line, TumorCell ProliferationCell SurvivalDeubiquitinating EnzymesEnzyme InhibitorsGene Expression Regulation, NeoplasticGoldHumansLeukemia, Myeloid, AcuteLung NeoplasmsMiceMice, NudeOrganogold CompoundsOrganophosphorus CompoundsDeubiquitinating EnzymesEnzyme InhibitorsGoldOrganogold CompoundsOrganophosphorus CompoundsOrganoplatinum Compounds

Identifiers

PMID30527624
PMCPMC6354570
OpenAlexW2903375420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.